|
Jul 21
|
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
|
|
Jul 21
|
Fangzhou and Novo Nordisk link on chronic disease management
|
|
Jul 21
|
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
|
|
Jul 18
|
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
|
|
Jul 18
|
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
|
|
Jul 18
|
Is Europe losing the AI race? Magnificent Seven widen gap over Europe's giants
|
|
Jul 17
|
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
|
|
Jul 16
|
Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder
|
|
Jul 16
|
Trump threatens tariffs on medicines within weeks
|
|
Jul 16
|
Health Care Roundup: Market Talk
|
|
Jul 16
|
Many US employers plan to pare health benefits as weight-loss spending soars
|
|
Jul 15
|
Hims & Hers Health, Inc. (HIMS) Announces Expansion To Canada
|
|
Jul 15
|
Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo
|
|
Jul 15
|
Connecticut wants to make generic GLP-1s. Will RFK Jr. lend a hand?
|
|
Jul 15
|
Here's How to Play AbbVie Stock as it Reaches Golden Cross
|
|
Jul 15
|
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
|
|
Jul 15
|
3 Absurdly Cheap Growth Stocks to Load Up On Right Now
|
|
Jul 14
|
Temasek eyes more Indian family-run businesses after Haldiram's deal
|
|
Jul 14
|
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Research Report 2025 | Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements
|
|
Jul 13
|
NVIDIA (NVDA) Announces Collaboration with Novo Nordisk
|